About Us   |   Contact Us
An International Publisher for Academic and Scientific Journals
Author Login 
 Author Login
Submit Manuscript
Join Membership
Join As Reviewer
Join As Editor
Pay Publication Fee
Subscribe Hard Copy
SAS Journal of Surgery | Volume-10 | Issue-04
Corticosteroid Sclerotherapy of Morel-Lavallée Syndrome: about a Case at the Reference Health Center (CSRéf) Commune III of Bamako
Sanogo, S, Karembé, B, Diallo, S, Albachar, H, Diarra, O, Fall, I, Coulibaly, C. A, Cissé, M, Cissé, L, Traoré, S, Sissoko H, Diakité, S. M, Traoré, S, Bah, D, Haidara, K, Kodio, S, Tounkara, C. M, Sa
Published: April 30, 2024 | 31 29
DOI: 10.36347/sasjs.2024.v10i04.029
Pages: 522-525
Downloads
Abstract
Morel-Lavallée syndrome corresponds to a serolymphatic effusion secondary to tangential trauma in relation to a richly vascularized tissue. It is a pathology little mentioned in the medical literature. We report the case of a female patient, victim of a road traffic accident which caused a Morel-lavallée lesion and who was successfully treated by sclerotherapy with corticosteroid (triamcinolone). There is currently no universally accepted treatment algorithm for the management of Morel-Lavallée lesions. Corticosteroids constitute a valid therapeutic option as a sclerosing agent in the treatment of this pathology. Conclusion: Corticosteroids constitute a valid therapeutic option as a sclerosing agent in the treatment of Morel-lavallée syndrome with satisfactory results.